ICON 2019--International Scientific Tendinopathy Symposium Consensus: There are 9 core health-related domains for Tendinopathy (CORE DOMAINS): A Delphi Study of Health Care Professionals and Patients

Authors: Bill Vicenzino1, Robert-Jan de Vos2, Håkan Alfredson3, Roald Bahr4,5, Jill Cook6, Brooke K Coombes7, Sheung Wan (Amy) Fu8, Karin Gravare Silbernagel9, Alison Grimaldi1,10, Jeremy Lewis11,12, Nicola Maffuli13, Stig Peter Magnusson14,15, Peter Malliaras16, Sean McAuliffe5, Edwin HG Oei17, Craig Purdam6, Jonathan D Rees18,19, Ebonie Rio6, Alexander Scott20, Cathy Speed21, Inge van den Akker-Scheek22,23, Adam Weir2,24,25, Jennifer Moriatis Wolf26, Johannes Zwerver24

Affiliations:
1 The University of Queensland: School of Health & Rehabilitation Sciences, St Lucia Campus: Therapies Annexe (84-A) Brisbane, Australia
2 Department of Orthopaedics and Sports Medicine, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
3 Sports Medicine Unit, University of Umeå, Sweden, University of Umeå, Sweden Umeå, Sweden
4 Oslo Sports Trauma Research Center, Norwegian School of Sport Sciences Oslo, Norway
5 Aspetar Orthopedic and Sports Medicine Hospital, Doha, Qatar
6 La Trobe University Sport and Exercise Medicine Research Centre, Kingsbury Drive, Bundoora Melbourne, Australia
7 Griffith University, 170 Kessels Road, Nathan, QLD 4111 Brisbane, Australia
8 Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Yuk Choy Road, Hung Hom, Kowloon Hong Kong, Hong Kong (SAR)
9 Department of Physical Therapy, University of Delaware, 540 South College Avenue Newark, Delaware, USA
10 Physiotec, Tarragindi Brisbane, Australia
11 University of Hertfordshire, School of Health and Midwifery Hertfordshire, UK
12 Central London Community Healthcare NHS Trust, London London, UK
13 Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery, University of Salerno, 84081 Baronissi Salerno, Italy
14 Department of Physical Therapy, Bispebjerg Hospital Copenhagen, Denmark
15 Department of Sports Medicine, Bispebjerg Hospital Copenhagen, Denmark
16 Department of Physiotherapy, Monash University Melbourne, Australia
17 Erasmus MC, University Medical Center; Department of Radiology & Nuclear Medicine, Dr. Molewaterplein 40 Rotterdam, The Netherlands.
18 Fortius Clinic, 17 Fitzhardinge Street London, UK
19 Centre for Sports & Exercise Medicine, Queen Mary University of London, London UK
20 Department of Physical Therapy, Faculty of Medicine, University of British Columbia, 2177 Wesbrook Mall Vancouver, Canada
21 Sports Medicine & Human Performance, Cardiff metropolitan university, Cardiff, UK Cardiff, UK
22 University of Groningen, University Medical Center Groningen, Department of Sport and Exercise Medicine, Hanzeplein 1, PO Box 30.001, 9700RB Groningen, The Netherlands.
23 University of Groningen, University Medical Center Groningen, Department of Orthopaedics, Hanzeplein 1, PO Box 30.001, 9700RB Groningen, The Netherlands.
24 Aspetar Sports Groin Pain Centre, Aspetar Orthopaedic and Sports Hospital Doha, Qatar
25 Sport medicine and exercise clinic Haarlem (SBK), Haarlem, The Netherlands.
26 Department of Orthopaedic Surgery, University of Chicago, USA
Acknowledgements:
We gratefully acknowledge the patients who participated in both the online survey and face to face meeting. Thanks to Melanie Plinsinga, Megan Ross and Viana Vuvan for taking notes during and assisting in the running of the consensus meeting.
Abstract

Background:
The absence of any agree-upon tendon health-related domains hampers advances in clinical tendinopathy research. This void means that researchers report a very wide range of outcome measures inconsistently. As a result, substantial synthesis/meta-analysis of tendon research findings is almost futile despite researchers publishing busily. We aimed to determine options for, and then define, core health-related domains for tendinopathy.

Methods:
We conducted a Delphi study of health care professionals (HCP) and patients in a three-stage process. In Stage 1, we extracted candidate domains from clinical trial reports and developed an online survey. Survey items took the form: ‘The ‘candidate domain’ is important enough to be included as a core health-related domain of tendinopathy’; response options were: agree, disagree, or unsure. In Stage 2, we administered the online survey and reported the findings. Stage 3 consisted of discussions of the findings of the survey at the ICON consensus meeting. We set 70% participant agreement as the level required for a domain to be considered ‘core’; similarly, 70% agreement was required for a domain to be relegated to ‘not core’ (see results below).

Results:
Twenty-eight HCP (92% of whom had >10 years of tendinopathy experience, 71% consulted >10 cases per month) and 32 patients completed the online survey. Fifteen HCP and two patients attended the consensus meeting. Of an original set of 24 candidate domains, the ICON group deemed nine domains to be core. These were: (i) patient rating of condition, (ii) participation in life activities (day to day, work, sport), (iii) pain on activity/loading, (iv) function, (v) psychological factors, (vi) physical function capacity, (vii) disability, (viii) quality of life, and (ix) pain over a specified time. Two of these (ii, vi) were an amalgamation of five candidate domains. We agreed that seven other candidate domains were not core domains: range of motion, pain on clinician applied test, clinical examination, palpation, drop out, sensory modality pain and pain without other specification. We were undecided on the other five candidate domains of physical activity, structure, medication use, adverse effects and economic impact.

Conclusion:
Nine core domains for tendon research should guide reporting of outcomes in clinical trials. Further research should determine the best outcome measures for each specific tendinopathy (i.e., Core Outcome Sets).
Introduction:
If we review the past two decades of tendinopathy research it appears that progress in patient outcomes are on a plateau.\(^{(1,2)}\) One factor that may have limited progress is that few tendon studies have lent themselves to meta-analysis,\(^{(3,4)}\) so that the clinical and research community has not agreed on treatment guidelines for the major tendinopathies. A specific barrier to meta-analysis of tendon treatment studies is that the original research studies report many disparate outcome measures,\(^{(3-5)}\) most of which have not been validated.\(^{(6)}\) A pre-requisite for authors to be able to synthesise and meta-analyse research findings from different studies systematically is for numerous studies to contain similar outcome measures. It can help to guide a field of clinical research if core outcomes are proactively defined and established as a core outcome set.\(^{(7)}\)

Before a community of researchers adopt core outcomes widely, the key actors usually first agree on core domains. Let us explain the important difference and their logical sequence. The ultimate goal, a core outcome set—refers to validated outcome measures that capture core health-related domains specific to a condition that have been agreed upon by patients and health care professionals (HCP: clinicians and researchers). A very successful example comes from The Outcome Measures in Rheumatology (OMERACT) initiative\(^{(8)}\) where researchers and patients developed a conceptual framework to identify core domains (first) before defining a core outcome set.\(^{(9)}\) This approach guided our study and this consensus statement is limited to the first part—determining core domains. The next phase for tendon researchers, developing core outcome measures for specific tendinopathies is planned for 2020 and beyond.

We aimed to establish (health related) core domains for tendinopathy. We used a three-stage process: (i) a literature review of clinical trials on tendinopathy, which informed the items (candidate domains) to be included in an online survey, (ii) an online survey of HCP and patients seeking their opinion on key domains, and finally (iii) a consensus meeting of HCP and patients to make decisions on what should be the core domains.

Methods:
We conducted a consensus process involving HCP and patients, which commenced with some of us generating candidate domains from a review of literature (stage 1, June 2018). These candidate domains were then considered for their importance as core health-related domains in tendinopathy, first by online survey (stage 2, August 2018) and then at an in-person meeting at the 2018 International Scientific Tendinopathy Symposium (ISTS, Groningen, the Netherlands) (stage 3, September 2018). The consensus process described here was one of three separate projects discussed at the ISTS consensus meeting; the other two dealt with terminology\(^{(10)}\) and reporting of participant characteristics.\(^{(11)}\)

Participants:
To achieve a representative group of tendinopathy experts, we selected the HCP cohort based on their track record primarily, with consideration for a balance of different professional disciplines, sex, likely attendance at the ISTS consensus meeting and geographical distribution. The aim was to have an online cohort of approximately 30 participating HCP, with as many of these to attend the dedicated consensus meeting the day before the ISTS symposium. This number of participants is based on previous Delphi studies.
in similar areas and regarded as an optimal sample size to answer our research question. \textsuperscript{(12)} All participants signed an agreement (Appendix A) when they accepted the invitation to participate. This stipulated the expectations of participation, as well as the rules for the consensus process and authorship of publications.

We aimed to recruit at least 30 patients. For this we used two research databases of patients with verified upper and lower limb tendinopathies on clinical or clinical plus imaging examination in Brisbane and Melbourne (Australia). The patients on these databases were invited to complete the online survey. The head of the local scientific committee of ISTS at Groningen (JZ) asked two patients from their clinical research unit to participate during the consensus meeting. These patients were proficient in English so they could participate in the survey and engage in the English-language meeting.

Ethical approval was gained for the study from the University of Queensland, Australia Ethics Committee (Approval #2018001439) and informed consent was obtained from all participants.

Procedure Stage 1 - Identifying outcome measures and formulating a candidate domain list: The candidate domain list was formed by first undertaking a scoping review of published clinical trials in tendinopathy between 2008 and 2018. This generated 122 relevant papers and one investigator (BV) extracted all outcome measures reported in those trials. For rigour, a research assistant independently extracted outcomes from a random selection of 20\% of those papers, which were then cross-checked. The aim was to generate the broadest possible capture of outcomes from which the survey’s candidate domain list was derived.

To move from outcome measures to domains, investigators JZ, SM, ER, AS, BV, and AW then constructed a list of potential domains that would make up the items of the survey. The aim was not to consolidate domains at this stage, but to ensure that all outcomes were aligned to a potential domain. To guide us, we used the International Classification of Functioning (ICF) aligned (https://www.who.int/classifications/icf/en/) OMERACT core areas of (a) life impact, (b) pathophysiologica manifestations, (c) resource use, and (d) death. \textsuperscript{(9)}

Procedure Stage 2 - Online survey relating to candidate domains: The candidate domains formed the basis of the online survey (see Appendix B). Each candidate domain was included as a separate survey question taking the form ‘Is the domain “candidate domain” important enough to be included in a Core Domain Set for Tendinopathy?’ and included examples of the outcome measures that were aligned with the candidate domain (See Appendix B and Results for alignment).

Survey respondents had three options in response to each question: agree (yes), disagree (no), or unsure. The consensus committee (JZ, ER, AS, AW, SM, BV) made an a-priori criterion decision that $\geq 70\%$ of ‘agree’ responses would elevate a candidate domain into the ‘core’ and $\geq 70\%$ of disagree responses would relegate the candidate domain to not being considered as a core domain. \textsuperscript{(9,13)} The candidate domains that fell between these limits of agreement (‘unsure’) were the focus of our discussion session at the ISTS consensus meeting.
Procedure Stage 3 – ISTS2018 Consensus meeting:
The results from the online survey were collated (Appendix C) and circulated to all HCP and the two patients 10 days prior to the consensus meeting. At the consensus meeting, the candidate domains that had been voted as ‘unsure’ (i.e., not already included or excluded from the domain set), were discussed in turn. HCP and patients (i.e., the group members) then voted as to whether they ‘agreed’ or ‘disagreed’ with each candidate being a core domain (forced choice). As with the online survey, a domain had to earn ≥70% of the delegates’ votes for either ‘agree’ or ‘disagree’ to be classified into either of those categories.

Results:
Participants--HCP
Thirty HCP were invited to participate in the overall Delphi process (potentially all 3 stages) and 28 responded to the online survey (one did not respond within the timeframe and one withdrew after agreeing to participate due to personal reasons, unrelated to the survey). Most of the cohort were clinician-researchers with at least 11 years working in the field and most (68%) had actually suffered from tendinopathy personally at some point.

Of these 28 individuals, 15 (54%) attended the ISTS consensus meeting in Groningen on the 26th September 2018 (Table 1). The meeting group was representative of the online survey group in terms of sex, cases of tendinopathy consulted per month, years of clinical experience in the field of tendinopathy and having a tendinopathy. There were proportionally more physiotherapists than medical professionals at the meeting. There were no surgeons at the consensus meeting (Table 1).

Participants—patient partners
All 219 patients registered on the research centres’ databases were sent an email inviting them to participate in the survey, with 56 (26%) clicking on the survey link, of which 32 (57%) then provided consent and completed the survey. A 55-year old woman with Achilles tendinopathy not related to a specific sports participation and a 30-year-old man who was a former elite middle-distance runner with Achilles tendinopathy, both from Groningen, participated during the ISTS consensus meeting.

Domains:
Stage 1 resulted in 24 candidate domains (Table 2), which formed the basis of the questions in the Delphi process. In addition to these 24 candidate domains, we asked survey participants to nominate any potential (candidate) tendon health-related domains they would remove, add or combine/amalgamate. We collated responses from the survey and sent them in a report out to attendees 10 days before the ISTS consensus meeting in Groningen (Appendix C).

From the HCP online survey, three candidate domains reached the pre-determined ≥70% agree (or disagree) criterion. Pain on Activity/Loading and Disability were voted as core domains and Range of Motion voted as not appropriate to be a core domain.
From the patient online survey, 11 candidate domains were voted as core domains (see Appendix C). No candidate domains met the ≥70% disagree criterion. Pain on Activity/Loading was the only candidate domain that was voted into the core domain by both patients and HCP.

At the ISTS consensus meeting, attendees moved seven candidate domains from an ‘unsure’ status to ≥70% agreement which elevated them to core domain status (Table 2): These seven were: Patient Rating of Condition, Participation, Function, Psychological Factors, Physical Function Capacity, Quality of Life and Pain over a Specified Time. As explained in Table 2, Function is patient rated (e.g., as might be captured on a patient specific function scale) whereas Physical Function Capacity is a quantitative measure of function (e.g., strength measured on dynamometer).

Attendees at the ISTS consensus meeting amalgamated five separate candidate domains from the survey into two core domains. The core domain of Participation was introduced as an amalgamation of candidate domains of participation in sport, work and global participation. The core domain of Physical Function Capacity was the amalgamation of physical function and strength.

Table 2 about here

Seven candidate domains reached the ≥70% voting threshold for agreement that they should not serve as core domains (Table 2). Four of these involved clinician examination (i.e., pain on clinician examination, examination findings, palpation, range of motion). Pain without Further Specification (i.e., context) was deemed to be more precisely covered under the two domains, Pain on loading/activity and Pain over specified time. Drop outs and sensory modality specific pain were the others.

We were undecided on the other five candidate domains: physical activity, structure, medication use, adverse effects and economic impact.

An infographic that conveys the salient design features and results have been developed to assist in the implementation of the ICON 9 CORE DOMAINS.
Discussion

Brief overview of the findings (at the 70% core/not-core threshold)*:

<table>
<thead>
<tr>
<th>Core domains for tendinopathy</th>
<th>Not core domains of tendinopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patient Rating of Condition</td>
<td>• Range of Motion</td>
</tr>
<tr>
<td>• Pain on Activity/Loading</td>
<td>• Pain on Clinician Examination</td>
</tr>
<tr>
<td>• Participation (Daily Activities, Work, Sport)*</td>
<td>• Clinical Exam Findings</td>
</tr>
<tr>
<td>• Function</td>
<td>• Palpation</td>
</tr>
<tr>
<td>• Psychological Factors</td>
<td>• Drop Out</td>
</tr>
<tr>
<td>• Disability</td>
<td>• Sensory Modality Specific Pain</td>
</tr>
<tr>
<td>• Physical Function Capacity (incl. Strength)*</td>
<td>• Pain without Further Specification</td>
</tr>
<tr>
<td>• Quality of Life</td>
<td></td>
</tr>
<tr>
<td>• Pain over a specified timeframe</td>
<td></td>
</tr>
</tbody>
</table>

* see Table 2 for details (and for those candidate domains remaining undecided)

What might the nine core domains mean?
The nine core domains arguably reflect an understanding by HCP and patients of the nature of tendinopathy. They encompass both physical (e.g., Pain on Loading, aspects of Participation, Function, Physical Function Capacity, Disability), psychosocial (e.g., Psychological Factors, aspects of participation and Pain ratings) and overall status/life impact (e.g., Patient Rating of Condition and Quality of Life).

There was a 100% agreement that pain could not be measured without reference to context (e.g., either to an activity or over a defined period). That is, ratings of pain intensity should be made on the basis of some specific activity, loading or time point/timeframe.

Six of the seven core domains decided at the ISTS consensus meeting (2 having reached the 70% agree threshold prior at the survey stage) had reached the core domain inclusion criterion in the online survey of patients. The 6 core domains of Patient Rating of Condition, Participation, Function, Physical Function Capacity, Psychological Factors, and Quality of Life were agreed upon by both HCP and patients. This adds weight to our belief that these domains are meaningful health-related domains for tendinopathy. When HCP and patients agree on domains, OMERACT refers to them as ‘inner’ core domains. (9) We recommend that outcome measures used in research and clinical practice align with each of these core domains, but does not prevent the inclusion of other outcome measures.

What comes next? We will need to define core outcome measures:
The next stage is to establish the core outcome measures (i.e., core outcome sets) that align with each of the domains for the different regional tendinopathies. (9) Many of the domains specifically relate to tasks, activities, sports/recreational pursuits and work/occupations that load a specific tendon. For example, specific activities, tasks and sport/occupations that are associated with Achilles tendinopathy (e.g., distance running) are likely very different to those associated with patellar tendinopathy (e.g., jumping sports) or lateral elbow tendinopathy (e.g., racquet sports, golf, manual labour). Now that we have determined 9 core domains for tendinopathy the ICON group resolved to establish anatomic site-specific Working Groups to establish core outcome sets for each of the common tendinopathies. An
Structure morphology of tendon (as captured by tendon imaging modalities): Structure did not reach the 70% threshold to be considered a core domain. The survey resulted in 34% and 43% agreement by HCP and patients, respectively. After much discussion, there was 69% agreement by participants at the ISTS consensus meeting. The main issue for structure not being agreed as a core domain related to the issue of imaging. Imaging appearance of tendon has a variable/unclear relationship with symptoms and has low diagnostic utility over clinical assessment in many settings. Importantly, imaging is not always available so that would limit the feasibility of it being useful to capture a core domain. We resolved to form a Working Group to further explore imaging under the structure domain and to revisit the topic at the next ISTS meeting.

Alignment with OMERACT core areas: Eight of the 9 core domains reflect the life impact core area of OMERACT. Apart from Physical Function Capacity, no core domains aligned with the OMERACT core areas of (i) pathophysiological manifestations (e.g., Structure 69%, Palpation 13%, Range of Motion 11%), (ii) death (e.g., Drop out 6% agreement, Adverse effects approx. 60% agreement) or (iii) resource use (Economic Impact 40% agreement, Medication use circa 60% agreement).

An interesting outcome of the ICON Core Domain process was the poor representation of the OMERACT core area of pathophysiologic manifestations. The conventional/prevaling view of tendinopathy is that it is a local tissue pathology, which is plausibly/intuitively aligned with structure and function domains of the ICF, represented under pathophysiologic manifestations concept/area in the OMERACT schema. A clear signal of the current conceptualisation of tendinopathy being more than a local tendon condition is apparent from the 9 core tendinopathy domains not including many of the potential candidate domains that belong to the pathophysiologic manifestations area in OMERACT.

There was agreement at the meeting that candidate domains such as adverse events and medication (other treatments) use would be covered generically for all trials as per reporting guidelines (e.g., CONSORT). In summary, the core outcome domains for tendinopathy are predominantly of the OMERACT core area of life impact.

Candidate domains about which the group members disagreed were core domains: There was a prevailing view at the ISTS consensus meeting that candidate domains that were voted not to be core domains (≥70% disagree), may still retain use in the clinic. For example, Tendon Palpation and Range of Motion, while not core domains, will still be part of a clinical examination. Interestingly, the patient’s survey had these candidate domains as core (≥70% agree).

Another example, was that the measurement of Sensory Modality-Specific Pain with quantitative sensory testing was deemed to be of likely importance in stratification of groups of individuals with tendinopathy on the basis of prognosis and possibly predicting treatment outcomes, but not as a measure of a health-related nature and thus outcome.
**Strengths:**
A strength of the process we undertook in deciding these core domains for tendinopathy, was that it involved individuals of both sexes, experienced in either treating/researching tendinopathy from a range of professions and countries. We also surveyed patients who had been diagnosed with tendinopathy by a HCP and involved two local patients in the ISTS consensus meeting. That along with many of the HCP having also experienced tendinopathy provides a level of assurance that the core domains for tendinopathy are meaningful entities representing health-related domains of patients with tendinopathy. The research was conducted independent of any funding source (e.g., pharma, health care profession associations, sponsors).

**Limitations:**
We were only able to have two local patients at the face-to-face ISTS consensus meeting and the online survey of patients was only conducted in Australia. This imposes a caveat on interpreting the patient survey responses, especially on the candidate domains of Physical Activity Levels, Medication Use, Clinical Examination findings and Range of Motion (Table 2). Notwithstanding this, the patient views at the consensus meeting appeared to align with the online survey.

The discussion on the structure (imaging largely) candidate domain raised the issue that we only engaged a single radiologist in the Delphi study. This was slightly offset by the three sports medicine physicians and 3 physiotherapists who all had published imaging studies in collaboration with radiologists. The meeting decided that further work on imaging (structure) was required and should include greater involvement of musculoskeletal radiologists who are expert in tendinopathies.

**ICON group recommends that:**
(a) Clinical trials should include a measure for each of the 9 core domains at a minimum, so that future meta-analyses will likely provide better estimates of treatment effects.
(b) These core domains should be used alongside clinical trial reporting guidelines (e.g., CONSORT) when conducting and reporting clinical trials.
(c) In future, core outcome sets need to be established for each of the common tendinopathies (e.g, Achilles tendon, lateral elbow tendon), using these 9 core domains as the guide (and an update reported at the future ISTS). This should identify outcome measures that are valid, responsive and feasible as per OMERACT.
(d) A special interest group including specialist radiologists and clinician scientists who regularly use imaging in their practice should discuss imaging further with a view to resolving whether tendon structure ought to be included as a core domain.
(e) The agreed core domains should not prevent the use of other outcomes in trials or clinical practice. That is, the core domains represent the minimal reporting requirement.
Accepted Manuscript.
Article accepted for publication in the British Journal of Sports Medicine, 04/11/2019.

References:


Accepted Manuscript.
Article accepted for publication in the British Journal of Sports Medicine, 04/11/2019.


CORE TENDINOPATHY DOMAINS TO BE REPORTED IN TRIALS

BACKGROUND

• Absence of agreed-upon tendon health-related domains hampers clinical tendinopathy research.
• We aimed to identify core health-related domains for tendinopathy.

THE PROCESS

1. LITERATURE REVIEW
   CANDIDATE DOMAINS EXTRACTED BY STEERING COMMITTEE

2. ONLINE SURVEY
   28 PROFESSIONALS
   30 PATIENTS

3. CONSSENSUS MEETING
   15 PROFESSIONALS
   2 PATIENTS

RESULTS

- 30-69% AGREEMENT
  - STRUCTURE
  - MEDICATION
  - ADVERSE EFFECTS
  - ECONOMIC COST
  - PHYSICAL ACTIVITY

<30% AGREEMENT
  - PAIN (NON-SPECIFIC)
  - DROP OUT
  - PAIN (clinical tests)
  - CLINICAL EXAM
  - Q.S.T
  - R.O.M

WHATS NEXT

• Future tendinopathy research should report on all 9 outcome domains.
• Further research should determine the best outcome measures for each specific tendinopathy (i.e. core outcome sets)

Infographic created by: Louise Vicenzino, Bill Vicenzino & Danny Glover
Table 1: Characteristics of the participants completing the online survey and attending the consensus meeting. Unless otherwise stated, data is n (%).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Survey Health Care Professionals</th>
<th>Survey Patients</th>
<th>Meeting Health Care Professionals</th>
<th>Meeting Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>28</td>
<td>31</td>
<td>15</td>
<td>2</td>
</tr>
<tr>
<td>Sex: Female</td>
<td>10 (36)</td>
<td>24 (77)</td>
<td>6 (40)</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Age: median (IQR; min-max) years years</td>
<td>53 (43-59; 29-64)</td>
<td>53 (32-61; 18-71)</td>
<td>46 (40-55; 29-64)</td>
<td>43 (36-49; 30-55)</td>
</tr>
<tr>
<td>Role:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinician only</td>
<td>0</td>
<td>1 (3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Researcher/Scientist only</td>
<td>5 (18)</td>
<td>0</td>
<td>3 (20)</td>
<td>0</td>
</tr>
<tr>
<td>Clinician and Researcher</td>
<td>23 (82)</td>
<td>0</td>
<td>12 (80)</td>
<td>0</td>
</tr>
<tr>
<td>Neither Clinician nor Researcher/Scientist</td>
<td>0</td>
<td>28 (97)</td>
<td>0</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Tendinopathy cases per month:</td>
<td></td>
<td>NA</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>None</td>
<td>5 (18)</td>
<td>3 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least 4</td>
<td>1 (4)</td>
<td>1 (6.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Between 5 and 10</td>
<td>2 (7)</td>
<td>2 (13.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Between 11 and 15</td>
<td>7 (25)</td>
<td>6 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than 16</td>
<td>13 (46)</td>
<td>3 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years managing tendon problems:</td>
<td>/27</td>
<td>NA</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>None</td>
<td>0</td>
<td>1 (6.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least 4</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Between 5 and 10</td>
<td>2 (4)</td>
<td>3 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Between 11 and 15</td>
<td>6 (22)</td>
<td>3 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than 16</td>
<td>19 (70)</td>
<td>8 (53.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highest academic qualification:</td>
<td>/26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undergraduate</td>
<td>0</td>
<td>5 (16)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diploma/Certificate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bachelor</td>
<td>0</td>
<td>14 (45)</td>
<td>0</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Master</td>
<td>1 (4)</td>
<td>4 (13)</td>
<td>0</td>
<td>1 (50)</td>
</tr>
<tr>
<td>PhD</td>
<td>23 (88)</td>
<td>5 (16)</td>
<td>13 (86.7)</td>
<td>0</td>
</tr>
<tr>
<td>Clinical Doctorate</td>
<td>2 (8)</td>
<td>0</td>
<td>1 (6.7)</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>3 (10)</td>
<td>1 (6.7)</td>
<td>0</td>
</tr>
<tr>
<td>Health care profession (Some cited more than one): ^</td>
<td>Physiotherapy 13 (40.6)</td>
<td>9 (56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sports &amp; Exercise Medicine physician</td>
<td>8 (28.6)</td>
<td>3 (18.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthopaedic surgery</td>
<td>4 (12.5)</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatology</td>
<td>3 (9.4)</td>
<td>1 (6.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiology</td>
<td>1 (3.1)</td>
<td>1 (6.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human movement science</td>
<td>1 (3.1)</td>
<td>1 (6.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td>1 (3.1)</td>
<td>1 (6.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>1 (3.1)</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Currently have tendon problem: | 8 (29) | 26 (84) | 4 (26.7) | 2 (100)
---|---|---|---|---
Past history of tendon problem: | 19 (68) | 21 (68) | 10 (66.7) | 1 (50)
Country where work: | | | | |
Australia | 8 (28.6) | 31 (100) | 5 (33.3) | |
United Kingdom | 5 (17.9) | | 1 (6.7) | |
The Netherlands | 5 (17.9) | | 4 (26.7) | 2 (100)
Canada | 2 (7.1) | | 1 (6.7) | |
USA | 2 (7.1) | | 1 (6.7) | |
Denmark | 2 (7.1) | | 1 (6.7) | |
Qatar | 1 (3.6) | | 1 (6.7) | |
Sweden | 1 (3.6) | | 0 | |
Hong Kong | 1 (3.6) | | 1 (6.7) | |
Norway | 1 (3.6) | | 0 | |

^ 2 (6.5) physiotherapists, 1 (3.2) nurse midwife, 1 (3.2) social worker, 1 (3.2) athlete
Abbreviations: N - Number, IQR – Interquartile Range, PhD - Doctor of Philosophy, USA – United States of America.
Table 2: Domains considered in the meeting in response to the question ‘Is the ‘candidate domain (item)’ important enough to be included in a core domain set for tendinopathy?’ Note that the citations placed in the definition column are only examples of some authors reporting of indicative outcome measures and they are not to be read as endorsing either the outcomes or their use.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Description/definition (Example Outcome)</th>
<th>Consensus meeting %</th>
<th>Survey (HCP; P) %</th>
<th>Some typical consensus meeting discussion points.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Core Domains (Candidate domains (Items) agreed ≥70% agree)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant/Patient Rating Overall Condition</td>
<td>A single assessment numerical evaluation (e.g., Rate your tendon status where 100% is no problems and 0% worst case scenario, Global Rating of Change (how are you now compared to prior treatment) (1-3), Patient Acceptable Symptom Status (is your current symptom level acceptable?)).</td>
<td>100</td>
<td>61, 91</td>
<td>Considered to be the most patient-centered candidate domain.</td>
</tr>
<tr>
<td>Participation</td>
<td>A patient rating of the level of participation/engagement across areas of their life. (e.g., Ratings of level of sport and time to return to sport).(4)</td>
<td>94</td>
<td>^</td>
<td>This resulted from the discussion on the three candidate domains considered in the survey and at the meeting, which were Overall, Sport and Work participation. With the exception of the Sport participation domain where the patients agreed it ought to be a core domain, this candidate domain did not reach agreement in the survey. Comments in the survey suggested amalgamation, which was supported at the meeting.</td>
</tr>
<tr>
<td>Overall</td>
<td>(e.g., Time to return to work, level of work (strenuousness)).</td>
<td>^</td>
<td>25, 65</td>
<td></td>
</tr>
<tr>
<td>Sport Participation</td>
<td></td>
<td>^</td>
<td>57, 74</td>
<td></td>
</tr>
<tr>
<td>Domain</td>
<td>Description</td>
<td>Refs</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Work Participation</strong></td>
<td>Participant/patient reported intensity of pain on performing a task/activity that loads the tendon. (e.g., VAS or NRS for pain intensity when the patient performs a tendon-specific pain-provocative task)(5-7).</td>
<td>^ 46, 65</td>
<td>This was strongly agreed at the survey by both patients and HCP. Note that there were no disagreements. Tendon specific loading tests would need to be determined (e.g., pain on gripping an object by a patient with lateral elbow tendinopathy).</td>
<td></td>
</tr>
<tr>
<td><strong>Function</strong></td>
<td>Participant/patient rated level of function (and not referring to the intensity of their pain). (e.g., Patient Specific Function Scale on a VAS or NRS).(2)</td>
<td>88 68, 87</td>
<td>Discussion centered around possible interdependence with Disability, which was resolved by considering this candidate domain as 'how much can the patient do' as opposed to the level of disability due to the pain.</td>
<td></td>
</tr>
<tr>
<td>Psychological factors</td>
<td>Psychology (e.g., Pain Self Efficacy, Pain Catastrophisation, Kinesiophobia, Anxiety or Depression Scales). (2)</td>
<td>88 36, 77</td>
<td>There was some concern regarding interdependence with quality of life, both at the meeting and HCP survey. It was agreed that psychology was sufficiently important and broader than covered in quality of life.</td>
<td></td>
</tr>
<tr>
<td>Physical Function Capacity</td>
<td>Quantitative measures of physical tasks performed in clinic (e.g., Number of hops, timed stair walk, number of single limb squats, including dynamometry (strength) and wearable technology). (2,8,9)</td>
<td>88 57, 68</td>
<td>Some discussion about the differences between this and 'Function', but resolved as this is a quantitative measure of the physical capacity (e.g., number of repetitions or time to do a task, muscle force/torque) and not a patient rating of their function (e.g., measured with a patient specific function scale).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muscle capacity or ‘Strength’ as it was considered in the survey and meeting.</td>
<td>^ 36, 91</td>
<td>Muscle capacity of strength was merged under Physical Function Capacity as it was considered a physical function measure and there was a high patient agreement at survey. It was rejected as a separate domain at the meeting (12.5% agree)</td>
<td></td>
</tr>
</tbody>
</table>
**Disability**  
Composite scores of a mix of patient rated pain and disability due to the pain, usually relating to tendon-specific activities/tasks. (e.g., VISA scales, Patient Rated Tennis Elbow Evaluation, Disability of the Arm, Shoulder and Hand).

* 86, 69  
This was agreed at the survey stage and not discussed at the meeting.

**Quality of Life**  
The general well being of the individual (specific QoL questionnaires such as EQ-5D, AQoL, SF-36).

75  
57, 91  
There was concern that there is no tendon specific QoL measure, but that the overall well being of the individual was important to include as a domain.

**Pain over a specified time**  
Participant reported pain intensity over a period of time (morning, night, 24 hours, a week) (e.g., VAS, NRS).

75  
32, 69  
The initial candidate domain was pain over 24 hours, but also referred to a period of time. After discussion it was agreed that it was the 'timeframe' being specified that provided more utility (e.g., for some tendons morning pain, others night).

<table>
<thead>
<tr>
<th>Candidate domains (Items) not reaching ≥70% agree</th>
</tr>
</thead>
</table>
| **Physical Activity**  
Overall physical activity levels (e.g., Self report of physical activity levels, wearable sensor technology). |
| 69  
54, 81  
Discussion centered around possible interdependence and overlap with other domains. Along with this being less specific to tendinopathy compared to what some of the other domains might be, it did not reach agreement). The 69% agreement could be viewed as indicating the overlap concern, but that this domain was one requiring further consideration. |

| **Structure**  
Tendon tissue characteristics (e.g., MRI, US, biopsy). |
| 69  
43, 34  
An extended discussion was had on this candidate domain, with some of the issues being: relationship to symptoms, diagnostic utility, technological, and availability of imaging modalities). It was decided to |
convene a group specific to imaging to deal with this candidate domain.

<table>
<thead>
<tr>
<th>Core Domains</th>
<th>Medication use</th>
<th>Medicines used (e.g., Patient Report or Record of type and dose).</th>
<th>63</th>
<th>57, 74</th>
<th>The direct relevance of medication use to tendinopathy was a feature of the discussion. It was also considered that it would be captured under other reporting guidelines for clinical trials.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adverse events</td>
<td>Unwanted unintended effects of treatments (e.g., Patient report or Medical record).</td>
<td>56</td>
<td>50, 58</td>
<td>Uncertainty about it being specific to tendinopathy, how to define it (e.g., pain after exercise), and how to measure it. Discussion also considered that adverse effects are usually reported under harms as per the CONSORT guidelines.</td>
</tr>
<tr>
<td></td>
<td>Economic impact: costs</td>
<td>Financial impost of the condition and its management (e.g., Patient report or Medical record).</td>
<td>40</td>
<td>29, 55</td>
<td>There was an extended discussion, largely around relevancy, societal impact (funding for health care and associated research), and how to measure it.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Not Core Domains (≥70% disagree)</th>
<th>Pain elicited with clinician applied stress/examination</th>
<th>Rating of pain when a clinician does an examination of the patient. (e.g., VAS or NRS for pain intensity).</th>
<th>21</th>
<th>18, 61</th>
<th>Considered more to be for diagnosis and selection into studies.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical examination findings</td>
<td>Clinician report of examination findings (e.g., Usually a composite score of a number of clinical exam tests).</td>
<td>13</td>
<td>29, 75</td>
<td>Considered important in a clinical examination, but the composite nature was not meaningful as an outcome.</td>
</tr>
<tr>
<td></td>
<td>Palpation</td>
<td>Manual pressure elicited/evoked pain over the tendon (e.g., VAS, NRS).</td>
<td>13</td>
<td>39, 68</td>
<td>Considered not to be related to resolution and difficult for some tendons (e.g., Shoulder versus Achilles).</td>
</tr>
<tr>
<td></td>
<td>Range of Motion</td>
<td>Range of motion (e.g., Goniometer, Inclinometer).</td>
<td>*</td>
<td>11, 84</td>
<td>75% disagree HCP survey and not voted at the meeting.</td>
</tr>
</tbody>
</table>
Drop out or discontinue treatment
Ceasing a treatment (e.g., Patient or Clinical record).

Sensory modality specific pain
Pain thresholds/tolerance to sensory stimulation (e.g., Quantitative Sensory Testing).

Pain without further specification
Patient asked about their pain without reference to activity or timeframe (e.g., VAS, NRS).

While considered important to be reported in clinical trials, it was not a key domain. Re-iteration that candidate domains like this should still be reported as per other guidelines of reporting.

Considered likely useful in sub-grouping studies but not as an outcome for trials.

Covered better in pain on loading and over a specified timeframe.

* Met the agreed criterion prior to meeting and thus not discussed at the meeting
^ Amalgamated items (candidate domains)

References to table 2 (cited as examples of some of the possible outcome measures):